Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight.

The word from the FDA is that Prasad has come back at the request of the regulator's Commissioner, Marty Makary, who appointed Prasad to the CBER position in May. Endpoints first reported his return on Saturday, and that was confirmed by the FDA shortly thereafter.